103 related articles for article (PubMed ID: 9259407)
1. New nortriterpenoid isolated from anti-rheumatoid arthritic plant, Tripterygium wilfordii, modulates tumor growth and neovascularization.
Ushiro S; Ono M; Nakayama J; Fujiwara T; Komatsu Y; Sugimachi K; Kuwano M
Int J Cancer; 1997 Aug; 72(4):657-63. PubMed ID: 9259407
[TBL] [Abstract][Full Text] [Related]
2. Antiangiogenic effect of celastrol on the growth of human glioma: an in vitro and in vivo study.
Zhou YX; Huang YL
Chin Med J (Engl); 2009 Jul; 122(14):1666-73. PubMed ID: 19719969
[TBL] [Abstract][Full Text] [Related]
3. Harmine inhibits tumour specific neo-vessel formation by regulating VEGF, MMP, TIMP and pro-inflammatory mediators both in vivo and in vitro.
Hamsa TP; Kuttan G
Eur J Pharmacol; 2010 Dec; 649(1-3):64-73. PubMed ID: 20858484
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor-induced angiogenesis by a synthetic lipid A analogue with low endotoxicity, DT-5461.
Sato K; Yoo YC; Mochizuki M; Saiki I; Takahashi TA; Azuma I
Jpn J Cancer Res; 1995 Apr; 86(4):374-82. PubMed ID: 7539783
[TBL] [Abstract][Full Text] [Related]
5. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
Takano S; Gately S; Neville ME; Herblin WF; Gross JL; Engelhard H; Perricone M; Eidsvoog K; Brem S
Cancer Res; 1994 May; 54(10):2654-60. PubMed ID: 7513254
[TBL] [Abstract][Full Text] [Related]
6. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice.
Min HY; Doyle LV; Vitt CR; Zandonella CL; Stratton-Thomas JR; Shuman MA; Rosenberg S
Cancer Res; 1996 May; 56(10):2428-33. PubMed ID: 8625323
[TBL] [Abstract][Full Text] [Related]
7. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
8. Ursolic acid inhibits colorectal cancer angiogenesis through suppression of multiple signaling pathways.
Lin J; Chen Y; Wei L; Hong Z; Sferra TJ; Peng J
Int J Oncol; 2013 Nov; 43(5):1666-74. PubMed ID: 24042330
[TBL] [Abstract][Full Text] [Related]
9. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo.
Oikawa T; Sasaki M; Inose M; Shimamura M; Kuboki H; Hirano S; Kumagai H; Ishizuka M; Takeuchi T
Anticancer Res; 1997; 17(3C):1881-6. PubMed ID: 9216639
[TBL] [Abstract][Full Text] [Related]
10. Inhibitory effects of Physalis angulata on tumor metastasis and angiogenesis.
Hseu YC; Wu CR; Chang HW; Kumar KJ; Lin MK; Chen CS; Cho HJ; Huang CY; Huang CY; Lee HZ; Hsieh WT; Chung JG; Wang HM; Yang HL
J Ethnopharmacol; 2011 Jun; 135(3):762-71. PubMed ID: 21515352
[TBL] [Abstract][Full Text] [Related]
11. Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo.
Strüh CM; Jäger S; Kersten A; Schempp CM; Scheffler A; Martin SF
PLoS One; 2013; 8(4):e62168. PubMed ID: 23614029
[TBL] [Abstract][Full Text] [Related]
12. Reduction of metastatic and angiogenic potency of malignant cancer by Eupatorium fortunei via suppression of MMP-9 activity and VEGF production.
Kim A; Im M; Yim NH; Ma JY
Sci Rep; 2014 Nov; 4():6994. PubMed ID: 25385232
[TBL] [Abstract][Full Text] [Related]
13. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin.
Mishima K; Mazar AP; Gown A; Skelly M; Ji XD; Wang XD; Jones TR; Cavenee WK; Huang HJ
Proc Natl Acad Sci U S A; 2000 Jul; 97(15):8484-9. PubMed ID: 10890917
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of cell-surface urokinase-type plasminogen activator activity and cell migration in vascular endothelial cells by a novel hexapeptide analogue of neurotensin.
Ushiro S; Mizoguchi K; Yoshida S; Jimi S; Fujiwara T; Yoshida M; Wei ET; Kitabgi P; Amagaya S; Ono M; Kuwano M
FEBS Lett; 1997 Dec; 418(3):341-5. PubMed ID: 9428741
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic activity of Andrographis paniculata extract and andrographolide.
Sheeja K; Guruvayoorappan C; Kuttan G
Int Immunopharmacol; 2007 Feb; 7(2):211-21. PubMed ID: 17178389
[TBL] [Abstract][Full Text] [Related]
16. [Effect of triptolide on expression of urokinase-type plasminogen activators in vascular endothelial cells].
Ding Y; Zhang J; Zhao QL; Hou LJ; Wang QL; Wang SR
Ai Zheng; 2005 Jul; 24(7):801-5. PubMed ID: 16004804
[TBL] [Abstract][Full Text] [Related]
17. [Several monomes from Tripterygium wilfordii inhibit proliferation of glioma cells in vitro].
Zhou YX; Huang YL; Xu QN; Ye M; Sun CF; Zhou D
Ai Zheng; 2002 Oct; 21(10):1106-8. PubMed ID: 12508653
[TBL] [Abstract][Full Text] [Related]
18. A hybrid protein comprising ATF domain of pro-UK and VAS, an angiogenesis inhibitor, is a potent candidate for targeted cancer therapy.
Sun Q; Xu Q; Dong X; Cao L; Huang X; Hu Q; Hua ZC
Int J Cancer; 2008 Aug; 123(4):942-50. PubMed ID: 18528863
[TBL] [Abstract][Full Text] [Related]
19. Hypoestoxide, a natural nonmutagenic diterpenoid with antiangiogenic and antitumor activity: possible mechanisms of action.
Ojo-Amaize EA; Nchekwube EJ; Cottam HB; Bai R; Verdier-Pinard P; Kakkanaiah VN; Varner JA; Leoni L; Okogun JI; Adesomoju AA; Oyemade OA; Hamel E
Cancer Res; 2002 Jul; 62(14):4007-14. PubMed ID: 12124334
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activator is induced in migrating capillary endothelial cells.
Pepper MS; Vassalli JD; Montesano R; Orci L
J Cell Biol; 1987 Dec; 105(6 Pt 1):2535-41. PubMed ID: 3121633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
